Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AVAXIM 80U Pediatric vaccine
Hepatitis A vaccine AVAXIM 80U · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Hepatitis A vaccine AVAXIM 80U | BIOLOGICAL | 0.5 mL, Intramuscular |
| Hepatitis A vaccine (HAVRIX 720) | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria : Inclusion criteria to be checked at the screening visit (SC): 1. Toddlers, children and adolescents: Sub-Group 1: from 12 months to 3 years of age on the day of inclusion Sub-Group 2: from 4 to 6 years of age on the day of inclusion Sub-Group 3: from 7 to 9 years o...
Top 6 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Viread, Tenofovir alafenamide |
| Vir Biotechnology, Inc. | VIR | 6 | PHASE3 | Tobevibart, Elebsiran |
| Bausch Health Companies Inc. | BHC | 1 | PHASE3 | Larsucosterol |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Daplusiran/Tomligisiran, Bepirovirsen |
| Aligos Therapeutics, Inc. | ALGS | 1 | PHASE2 | ALG-000184 |
| Precision BioSciences, Inc. | DTIL | 2 | PHASE1 | PBGENE-HBV |
AVAXIM 80U is a vaccine developed by Sanofi for the prevention of hepatitis A. It is a pediatric formulation intended for use in children, with clinical study enrollment beginning at 12 months of age. The vaccine is designed to protect against hepatitis A virus infection.
AVAXIM 80U is made by Sanofi, a global pharmaceutical company. Sanofi trades on the New York Stock Exchange under the ticker symbol SNY. The vaccine is part of Sanofi's hepatitis A vaccine portfolio.
AVAXIM 80U has been studied in a Phase 3 clinical trial. The trial has been completed. The vaccine is an investigational product in the context of this trial, and the data describe a completed Phase 3 study rather than a marketed product.
AVAXIM 80U has been evaluated in one clinical trial, NCT00483470, titled Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose. The trial was a completed Phase 3 study with 720 participants, conducted in China, and used an active-controlled, randomized design.
The AVAXIM 80U pediatric vaccine is a hepatitis A vaccine developed by Sanofi. It was tested in a Phase 3 trial in China involving 720 children from 12 months of age. The study assessed immunogenicity and safety, followed by a booster dose.